Partnering opportunity

Development of actinobacterial platforms for production of natural products using genetic engineering tools and omics techniques

Summary

A Spanish biotechnological institute offers their research experience in Streptomyces, Corynebacterium and Mycobacterium, molecular biology, synthetic biology and technical capabilities, including omics tools (genomics, transcriptomics, proteomics), to develop platforms for production of natural products (antibiotics, immunosuppressants, etc). Industrial/academic partners from pharma are sought for services and research agreement to prepare proposals for European and collaborative projects.

Partner sought

The biotechnology institute is looking for academic and industrial partners in order to build collaborative projects in the area of biotechnology production of pharmaceuticals, based on advanced genetic engineering of Actinomycetes, genome, transcriptome and proteome analyses, as well as regulatory studies. The focus is on polyketide compounds and non-ribosomal peptides, including beta-lactams, showing antibiotic activities or acting as immunosuppressors or other biological activities. The institute is also interested in contact with industries, academia or research organizations, in the area of pharmaceuticals, interested in services agreement related with know how previously described.

Description

The organization is a Spanish biotechnological private non-profit research institute, founded in 1993, whose main activities are related to molecular biology and microbial biotechnology. The institution keeps close links with industrial research and innovation. The team covers several techniques and counts with a long experience in scientific research in European funded projects. The Institute’s research group of the molecular microbiology of Streptomyces is seeking partners to build collaborative projects. For this, the group would provide expertise in the following techniques: a) microbial culture techniques, including fermentation cultures for production of secondary metabolites and high pressure liquid chromatography (HPLC)-based quantification of products; b) gene cloning and genetic engineering techniques, including species that are difficult to modify, c) protein expression and purification, d) transcriptional regulation studies, including electrophoretic-mobility assays, footprinting assays, and bioinformatics of binding sites; e) transcriptomic analysis (both microarray and ribonucleic acid sequencing (RNA-seq); f) 2-D proteomics and mass spectrometry, g) bioinformatics, including genome sequencing. The specialized equipment for the transcriptomic studies includes homogenization/disruptors cell systems for nucleic acid or protein extraction, RNA analyses, real-time polymerase chain reaction (PCR) instrument for gene expression analysis and the platform for microarray transcriptomic. Workstations are available for bioinformatics. The specialized equipment for proteomics studies includes a chromatography system for protein purification, a bidimensional gel electrophoresis system, fluorescent gel and membrane scanners, and a matrix-assisted laser desorption/ionization of time of flight (MALDI TOF/TOF) mass spectrometer. The institute is also equipped with a pilot plant hosting, among others, a battery of four 5-liter fermenters, as well as HPLC apparatus to analyze secondary metabolites production. The research institute is looking for industrial and academic partners from pharma services agreements based on the know-how of the center. It is also interested in collaboration in order to prepare proposals for European projects as Horizon 2020 or Innovative Medicines Initiative (IMI) calls.

Advantages and innovations

As an example of the advantages of the actinobacterial platforms, the number and diversity of secondary metabolites produced by strains of the Streptomyces genus has been estimated in more than 10^5 different compounds, of which only a minor fraction is known. The known metabolites comprise about two-thirds of naturally occurring antibiotics and also other compounds of useful biological activities, such as immunosuppressants, antihelmintics, antitumorals, and herbicides. Streptomyces could be the source of new valuable antibiotics needed to treat ESKAPE infections (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). This actinobacterial platforms allows the access to new secondary metabolites produced by strains of the Streptomyces genus. Theses unknown metabolites could be the source of new valuable antibiotics, immunosuppressants, antihelmintics, antitumorals, and herbicides.

Development stage

Concept stage

Intellectual Property Rights (IPR)

Secret Know-how


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company